Car-T Therapy in Inflammatory Muscle Disease
Description
In this presentation Dr. Mozaffar will provide an update on the current state of the art on cell therapy in autoimmune myopathies.
Harnessing Car-T Cells for Neuromuscular Disease: Emerging Science and Therapeutic Potential*
Date: October 19, 2026
Time: 3:45 pm to 5:15 pm
Room: Seaglass
Track: Traditional Special Interest Group (SIG)
Session Description
This session will highlight the fundamental principles of CAR-T therapy, differentiate safety and tolerability profile of CAR-T therapies in cancer versus autoimmune disorders, and evaluate the emerging therapeutic applications of CAR-T in neuromuscular disorders, particularly in myasthenia gravis and myositis. Attendees will gain practical clinical insights, understand evolving safety frameworks, and be prepared to assess how these engineered immunotherapies may shape future care strategies for neuromuscular patients in general. The session will focus specifically on emerging data from experimental clinical use as well as recent and ongoing clinical trials in the lead indications of myasthenia gravis and immune mediated myopathies.
Learning Objectives
At the conclusion of this session, attendees will be able to:
- Describe the mechanism of action and therapeutic approach of CAR-T therapy in neuromuscular disease.
- Evaluate safety considerations, monitoring, and logistical challenges associated with CAR-T therapy.
- Review current and emerging treatment approaches for myasthenia gravis and myositis.
Speakers
- (Chair) Jinsy Andrews, MD, MSc, FANA
- (Co-Chair, Speaker) Tahseen Mozaffar, MD, FANA
- (Speaker) Ali A. Habibi, MD
- (Speaker) Christina Ulane, MD, PhD
Car-T Therapy in Autoimmune Neuromsucular Disorders - Clinical Trial Logistics and Safety
Description
In this presentation, Dr. Habib will describe multidisciplinary requirements for the development, administration and monitoring of CAR-T therapies and their observed safety in NMDs.
Car-T Therapy in Myasthenia Gravis
Description
In this presentation, Dr. Ulane will discuss how CAR T cell therapy is an emerging treatment for myasthenia gravis with the possibility for durable, medication-free remission.